Literature DB >> 11100885

Cytokine-mediated growth promotion of Kaposi's sarcoma and primary effusion lymphoma.

B Ensoli1, M Stürzl, P Monini.   

Abstract

Kaposi's sarcoma (KS) is an angioproliferative disease particularly frequent and aggressive in patients with AIDS but occurring also in post-transplant patients or in immunocompetent individuals of certain geographic areas. At least in its early stages, KS behaves as a reactive hyperplastic process mediated by inflammatory cytokines and angiogenic factors triggered or exacerbated by human herpesvirus-8 (HHV-8) infection. The HIV Tat protein appears to be responsible for the highly aggressive nature of AIDS-KS. Over time, however, KS may evolve into a true sarcoma in association with the expression of oncogenes and/or HHV-8 latency genes endowed with growth and anti-apoptotic properties. HHV-8 infection is also associated with primary effusion lymphoma (PEL), a rare tumor that similarly develops more frequently in the setting of HIV infection. HHV-8 latency genes are likely to contribute to the neoplastic phenotype of PEL cells, whose growth in vivo may require cytokines and factors from the host, or encoded by the virus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11100885     DOI: 10.1006/scbi.2000.0329

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  32 in total

1.  Promoter- and cell-specific transcriptional transactivation by the Kaposi's sarcoma-associated herpesvirus ORF57/Mta protein.

Authors:  Diana Palmeri; Sophia Spadavecchia; Kyla Driscoll Carroll; David M Lukac
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

2.  Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta lytic switch protein functions as a tetramer.

Authors:  Wei Bu; Kyla Driscoll Carroll; Diana Palmeri; David M Lukac
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

3.  Mechanism of angiopoietin-1 upregulation in Kaposi's sarcoma-associated herpesvirus-infected PEL cell lines.

Authors:  Xin Zheng; Eriko Ohsaki; Keiji Ueda
Journal:  J Virol       Date:  2015-01-28       Impact factor: 5.103

4.  Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated herpesvirus.

Authors:  Melanie M Brinkmann; Marcel Pietrek; Oliver Dittrich-Breiholz; Michael Kracht; Thomas F Schulz
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

5.  Characterization of the Kaposi's sarcoma-associated herpesvirus K1 signalosome.

Authors:  Bok-Soo Lee; Sun-Hwa Lee; Pinghui Feng; Heesoon Chang; Nam-Hyuk Cho; Jae U Jung
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  Kaposi's sarcoma-associated herpesvirus promotes angiogenesis by inducing angiopoietin-2 expression via AP-1 and Ets1.

Authors:  Feng-Chun Ye; David J Blackbourn; Michael Mengel; Jian-Ping Xie; Li-Wu Qian; Whitney Greene; I-Tien Yeh; David Graham; Shou-Jiang Gao
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

7.  Angiogenic, lymphangiogenic and adipogenic effects of HIV-1 matrix protein p17.

Authors:  Daniele Basta; Olga Latinovic; Mark K Lafferty; Lingling Sun; Joseph Bryant; Wuyuan Lu; Francesca Caccuri; Arnaldo Caruso; Robert Gallo; Alfredo Garzino-Demo
Journal:  Pathog Dis       Date:  2015-09-01       Impact factor: 3.166

Review 8.  Gamma herpesviruses: pathogenesis of infection and cell signaling.

Authors:  J Rajcáni; M Kúdelová
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.099

9.  Induction of CCL20 production by Kaposi sarcoma-associated herpesvirus: role of viral FLICE inhibitory protein K13-induced NF-kappaB activation.

Authors:  Vasu Punj; Hittu Matta; Sandra Schamus; Tianbing Yang; Yuan Chang; Preet M Chaudhary
Journal:  Blood       Date:  2009-03-26       Impact factor: 22.113

10.  Non-human primate model of Kaposi's sarcoma-associated herpesvirus infection.

Authors:  Heesoon Chang; Lynn M Wachtman; Christine B Pearson; Jong-Soo Lee; Hye-Ra Lee; Steven H Lee; Jeffrey Vieira; Keith G Mansfield; Jae U Jung
Journal:  PLoS Pathog       Date:  2009-10-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.